Artivion Announces Executive and Board Changes
Ticker: AORT · Form: 8-K · Filed: Aug 11, 2025 · CIK: 784199
| Field | Detail |
|---|---|
| Company | Artivion, Inc. (AORT) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $540,000, $2,250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, personnel
TL;DR
Artivion shakes up exec team & board, names new CMO, adds director.
AI Summary
Artivion, Inc. announced on August 6, 2025, a series of executive and board changes. The company appointed Dr. Michael J. C. R. Davies as Chief Medical Officer and elected Dr. David L. Smith to its Board of Directors. Additionally, the company reported on compensatory arrangements for its named executive officers.
Why It Matters
These changes in leadership and board composition can signal shifts in strategic direction or operational focus for the medical device company.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Artivion, Inc. (company) — Registrant
- Dr. Michael J. C. R. Davies (person) — Appointed Chief Medical Officer
- Dr. David L. Smith (person) — Elected to Board of Directors
- August 6, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Michael J. C. R. Davies has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. David L. Smith has been elected to the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 6, 2025.
What other information is reported regarding executive officers?
The filing also reports on compensatory arrangements of certain officers.
What is the principal executive office address of Artivion, Inc.?
The principal executive office is located at 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144.
Filing Stats: 999 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2025-08-11 13:18:02
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value AORT NYSE Indicate by check
- $540,000 — pensation: (a) an annual base salary of $540,000; (b) annual cash incentive compensation
- $2,250,000 — n 2026, a target equity grant valued at $2,250,000, divided equally among the equity vehic
Filing Documents
- aort-20250806.htm (8-K) — 32KB
- 0000784199-25-000136.txt ( ) — 145KB
- aort-20250806.xsd (EX-101.SCH) — 2KB
- aort-20250806_lab.xml (EX-101.LAB) — 21KB
- aort-20250806_pre.xml (EX-101.PRE) — 12KB
- aort-20250806_htm.xml (XML) — 3KB
01(d) Exhibits
Item 9.01(d) Exhibits (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). -3-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Artivion, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 11, 2025 ARTIVION, INC. By: /s/ Jean F. Holloway Name: Jean F. Holloway Title: Senior Vice President, General Counsel, Chief Compliance Officer & Secretary. -4-